
BioMarin Pharmaceutical Inc.
BMRNHealthcare|Biotechnology|US
$56.03
-0.09 (-0.16%)
DCF Value
$7.43
Tangible Book / Share
$4.20
Cash / Share
$3.80
Next Earnings Report
Feb 22, 2027
EPS est. $0.82 · Revenue est. $1.09B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (21)
Mar 2027
Est. completion
P2Noonan Syndrome
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
NCT06668805n=30
Apr 2027
Est. completion
P1P2Duchenne Muscular Dystrophy
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT06280209n=18
Jul 2027
Est. completion
P1Claudication, Intermittent
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
NCT04800692n=10
Sep 2027
Est. completion
Dec 2027
Est. completion
P2Achondroplasia
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
NCT04554940n=20
Dec 2027
Est. completion
P2Achondroplasia
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
NCT02724228n=30
Dec 2027
Est. completion
Feb 2028
Est. completion
Jun 2028
Est. completion
P2Hypochondroplasia
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262n=60
Nov 2028
Est. completion
P1P2Hereditary Angioedema
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
NCT05121376n=44
Dec 2028
Est. completion
Phenylketonurias
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
NCT04404530n=45
Jun 2029
Est. completion
P2P3Achondroplasia
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
NCT07441876n=160
Aug 2030
Est. completion
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Cerliponase Alfa Observational Study in the US
NCT04476862n=35
Dec 2030
Est. completion
Jun 2031
Est. completion
P3Achondroplasia
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
NCT03424018n=119
Oct 2032
Est. completion
Phenylketonuria, Maternal
A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
NCT05579548n=50
Nov 2033
Est. completion
Phenylketonuria (PKU)
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678n=450
Nov 2033
Est. completion
Phenylketonuria (PKU)
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
NCT06305234n=200
May 2038
Est. completion
P2Achondroplasia
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
NCT03989947n=73
Dec 2040
Est. completion
Idiopathic Short Stature
A Study to Assess Growth in Children With Idiopathic Short Stature
NCT06309979n=300
Awaiting Results (4)
Trials past primary completion date but still active — data readout may be imminent.
Aug 2026
P3
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059Apr 2025
P3
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
NCT06224907Jan 2025
P3
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
NCT05270837Recent Press Releases
BioMarin to Participate in Upcoming Investor Conferences
Nov 4, 2026 · PRNewsWire
BioMarin Reports Third Quarter 2026 Financial and Operating Results
Nov 2, 2026 · PRNewsWire
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
Oct 29, 2026 · PRNewsWire
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
Oct 26, 2026 · PRNewsWire
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
Oct 9, 2026 · PRNewsWire
BioMarin Appoints Cara Bauer as Chief People Officer
Oct 5, 2026 · PRNewsWire
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
Oct 2, 2026 · PRNewsWire
Profluent Partners With BioMarin to Design Novel Medicines Using AI
Sep 30, 2026 · Business Wire
SEC Filings (69)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 4, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 3, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Nov 2, 2026 | 8-K | Material event | DocumentIndex |
| Oct 6, 2026 | 8-K | Material event | DocumentIndex |
| Sep 30, 2026 | 8-K | Material event | DocumentIndex |
| Sep 15, 2026 | 8-K | Material event | DocumentIndex |
| Sep 14, 2026 | 8-K | Material event | DocumentIndex |
| Sep 1, 2026 | 8-K | Material event | DocumentIndex |
| Aug 31, 2026 | 8-K | Material event | DocumentIndex |
| Aug 18, 2026 | 8-K | Material event | DocumentIndex |
| Aug 6, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Aug 6, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 6, 2026 | 8-K | Material event | DocumentIndex |
| Jul 13, 2026 | 8-K/A | Material event | DocumentIndex |
| Jun 4, 2026 | 8-K | Material event | DocumentIndex |
| May 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 4, 2026 | 8-K | Material event | DocumentIndex |
| Apr 29, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 27, 2026 | 8-K | Material event | DocumentIndex |
| Apr 23, 2026 | 8-K | Material event | DocumentIndex |
| Apr 21, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 21, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 21, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 26, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 16, 2026 | 8-K | Material event | DocumentIndex |
| Feb 26, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 23, 2026 | 8-K | Material event | DocumentIndex |
| Feb 12, 2026 | 8-K | Material event | DocumentIndex |
| Jan 29, 2026 | 8-K | Material event | DocumentIndex |
| Jan 26, 2026 | 8-K | Material event | DocumentIndex |
| Jan 21, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jan 12, 2026 | 8-K | Material event | DocumentIndex |
| Dec 22, 2025 | 8-K | Material event | DocumentIndex |
| Dec 19, 2025 | 8-K | Material event | DocumentIndex |
| Dec 17, 2025 | 8-K | Material event | DocumentIndex |
| Nov 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 28, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Oct 27, 2025 | 8-K | Material event | DocumentIndex |
| Oct 7, 2025 | 8-K | Material event | DocumentIndex |
| Aug 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |